MIGUEL JOSÉ
MARTÍN JIMÉNEZ
Catedrático de universidad
![Foto de MIGUEL JOSÉ](/img/nophoto.png)
![Foto de Bishop Auckland Hospital](/img/noimage_org.png)
Bishop Auckland Hospital
Bishop Auckland, Reino UnidoPublikationen in Zusammenarbeit mit Forschern von Bishop Auckland Hospital (3)
2023
-
Overall survival with neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): A randomised, double-blind, placebo-controlled, phase 3 trial
European Journal of Cancer, Vol. 184, pp. 48-59
2017
-
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial
The Lancet Oncology, Vol. 18, Núm. 12, pp. 1688-1700
2016
-
Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): A multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
The Lancet Oncology, Vol. 17, Núm. 3, pp. 367-377